In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
News|Podcasts|May 29, 2026
ACT Brief: Data Capture vs. Execution, Coordinator Performance Gaps, and COVID Vaccine Composition Vote
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why decades of data capture progress haven't solved trial execution, study coordinator performance on document reviews, and FDA advisors voting on updated COVID-19 vaccine composition.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a new video
interview , Abraham Gutman, founder and CEO of AG Mednet, explained why data capture advances have not addressed the underlying execution problem in clinical trials and what a practical operational architecture for AI actually looks like in real-world deployment. - A new
study published by Norman Goldfarb of the Site Council found study coordinators identify only 45% of critical and major problems during document reviews, with substantial variability across experience levels. However, focused training can improve detection rates from 45% to approximately 68%, with performance gaps highest in protocol requirements and lowest in delegation of authority. - The FDA's vaccine advisory panel is
voting on whether COVID-19 vaccines for 2026–2027 should target the XFG variant, based on CDC data more than a month old. The panel faces significant surveillance gaps including declining sequencing volumes and reduced state-local data sharing, leaving real-time variant assessment increasingly difficult.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
Trending on Applied Clinical Trials Online
1
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
2
How a Platform Approach Can Scale AI’s Impact in Life Sciences
3
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5